- Nearly 5000 pregnant women are infected with COVID-19
- Powell dies due to COVID-19 Also suffered Multiple Myeloma
- Hundreds millions of Nike shoes could not be delivered due to COVID-19
- How long is the protection period of COVID-19 vaccines?
- What are the differences between the current COVID-19 vaccines?
- Will EMT become the new target for the treatment of colorectal cancer?
Overview of the development of mRNA vaccines: Part Three
Part Three: mRNA vaccine vaccination and the mechanism of triggering immune response
- Israel new drug for COVID-19: EXO-CD24 can reduce deaths by 50%
- COVID-19 vaccines for children under 12 will be available soon
- Breakthrough infection of Delta: No difference from regular COVID-19 cases
- French research: ADE occurred in Delta variant and many doubts on it
- The viral load of Delta variant is 1260 times the original COVID-19 strain
Overview of the development of mRNA vaccines: Part Three.
Part Three: mRNA vaccine vaccination and the mechanism of triggering immune response
The location of the vaccination affects the induced immune response
In addition to the vaccine component itself, the method and location of delivery also affect its effectiveness (Figure 1). Vaccines are usually injected into muscle or subcutaneous fat tissue. Other non-traditional methods, such as transnasal, intrasplenic, intradermal, intranasal, intravenous, and tumors, are also widely used. The secondary lymphoid organs are characterized by the dense presence of a large number of immune cells, such as APC and T cells, which create an ideal place for effectively inducing adaptive immune responses. Dendritic cells are a highly specialized and heterogeneous subgroup of APCs, which link the innateness of pathogens with the activation of adaptive immunity.
Figure 1 Immune response induced by different positions of mRNA injection
The figure lists the advantages and disadvantages of the different methods. In general, direct transfection of APC with mRNA is not a necessary prerequisite to effectively induce an immune response. In principle, systemic injection is feasible. Direct injection of mRNA into secondary lymphoid tissues facilitates targeted antigen delivery to APC without DC migration. Intramuscular and intradermal injections of the vaccine can trigger longer-lasting protein expression. In addition, in one study, compared with intravenous injection, the half-life of luciferase encoded by intradermal mRNA was increased three times.
Once the mRNA molecule is released from LNP into the cytoplasm, it is sensed by toll-like receptors (TLR) such as TLR3 or 7/8 and retinoic acid-inducible gene (RIG)-I, which is promoted by retinoic acid-inducible gene (RIG)-I Type I interferon (IFN) is secreted into the extracellular matrix, creating an environment conducive to Th1 response rather than Th2 response. mRNA is directly translated into polypeptides by the ribosome, processed by the proteasome system, resulting in the presentation of peptides to MHC-I on the cell surface (similar to during viral infection), and post-translational modification to fold into proteins. According to the mRNA design, it can be a membrane Anchored or secreted. After the extracellular protein or cell debris containing the protein ingests the protein, peptide presentation on MHC-II may appear on the APC (Figure 2).
Figure 2 Reaction of cells ingesting LNP-coated mRNA vaccine
Figure 3 The effect of mRNA vaccine on immune function
a) The influence of exogenous mRNA on innate immunity. TLR in the endosome and receptors such as RIG-I and MDA5 in the cytoplasm can detect exogenous mRNA. dsRNA can induce a strong IFN1 response. Peptides derived from translated proteins will be processed in the proteasome and displayed on MHC-I and MHC-II molecules. b) The influence of exogenous mRNA on adaptive immunity. APC can present the foreign antigen on MHC-II to CD4+ T cells, and cross-present it on MHC-I to CD8+ T cells. CD4+ T cells provide help for B cells and CD8+ T cells. Finally, the clonal expansion of antigen-specific B and T cells leads to the elimination of target cells. c) The risk of tumor immune evasion. Tumors can create an immunosuppressive microenvironment by recruiting bone marrow-derived suppressor cells (MDSC), regulatory T cells, M2 macrophages and producing immunosuppressive cytokines. For example, the up-regulation of depletion markers on T cells or the loss of antigens on tumor cells can further promote immune evasion. CPI (Immune Checkpoint Inhibitor) may help regain immune surveillance.
Figure 4, Figure 5, and Figure 6 show how mRNA vaccines trigger natural immune responses.
Figure 4 The mechanism of innate immune response triggered by exogenous mRNA
The mRNA vaccine synthesized by IVT is recognized by PRR (including endosomal TLR3, -7 and -8, and cytoplasmic innate immune receptors RIG-I and MDA5). The dsRNA produced by the inaccurate T7 polymerase activity is recognized by TLR8 and RIG-I to induce the expression of pro-inflammatory cytokines and promote the expression of 2′-5′-oligoadenylate synthase/RNase L and PKR-dependent eIF2α phosphorylation mediated RNA degradation and translational inhibition.
Figure 5 mRNA in vitro transcription and innate immune activation
(A) In vitro transcription of mRNA. Using DNA with antigen coding sequence as a template, mRNA in vitro transcription products contain single-stranded RNA (ssRNA), double-stranded RNA (dsRNA), etc. The structure of ssRNA usually includes 5’cap, 5’UTR, open reading frame (ORF) region, 3’UTR and poly(A) tail structure
(B) RNA translation and antigen presentation. mRNA enters the cytoplasm through endocytosis. Some mRNAs bind to the ribosomes of the host cell and are successfully translated. Antigenic proteins can be degraded into antigen peptides by the proteasome in the cytoplasm, and presented to cytotoxic T lymphocytes (CTL) through the major histocompatibility complex (MHC) I pathway; alternatively, they can be released from host cells, And received by DCs. Then, they are degraded and presented to helper T cells and B cells through the MHC-II pathway. B cells can also recognize the released antigen protein
(C) Self-assisting effect. Various pattern recognition receptors (PRR) can recognize in vitro transcription products of mRNA. ssRNA can be recognized by endosomal innate immune receptors (such as Toll-like receptor 7 (TLR7), TLR8). dsRNA can be recognized by endosomal innate immune receptors (such as TLR3) and cytoplasmic innate immune receptors (PKR, RIG-I, MDA5 and OAS. On this basis, mRNA products can stimulate pro-inflammatory cytokines and type I interferons (IFN). ) Secretion, leading to the activation of antigen-presenting cells (APCs) and inflammation. However, they can also activate antiviral enzymes that cause mRNA translation stagnation and mRNA degradation.
Figure 6 Innate immune sensing of mRNA vaccine
Dendritic cells (DC) innate immunity to the two mRNA vaccines. The RNA sensor is shown in yellow, the antigen is shown in red, the DC maturation factor is shown in green, and the peptide-major histocompatibility complex (MHC) complex is shown Light blue and red; an example of a lipid nanoparticle carrier is shown in the upper right corner. The figure shows a non-exhaustive list of the main known RNA receptors that help to identify double-stranded and unmodified single-stranded RNA, select unmodified, unpurified (part a) and nucleoside modification, fast protein liquid chromatography (FPLC) Purified (part b) mRNA is used to illustrate two forms of mRNA vaccines, both with and without known forms of mRNA sensing. The dashed arrow indicates a decrease in antigen expression. Ag, antigen; PKR, interferon-induced, double-stranded RNA activated protein kinase; MDA5, interferon-induced helicase C domain-containing protein 1 (also called IFIH1); IFN, interferon; m1ψ, 1-methyl Pseudouridine; OAS, 2′-5′-oligoadenylate synthase; TLR, Toll-like receptor.
Figure 7 shows the mechanism by which mRNA vaccine triggers the body’s adaptive immune response.
Figure 7 Adaptive immune response triggered by mRNA vaccination
Local inflammation at the injection site promotes the infiltration of immune cells, including neutrophils, monocytes, myeloid dendritic cells (MDC) and plasmacytoid dendritic cells (PDC). Neutrophils can take up LNP efficiently, but monocytes and MDCs translate mRNA more efficiently. Type I interferon (IFN) is stimulated to secrete. The mRNA/LNP and protein antigens will diffuse, and the cells will migrate to the vaccine-draining lymph nodes. The presentation of antigen to T cells and the interaction of antigen with B cells occur at these sites. This causes the formation of a germinal center, which produces memory B cells that reside in the bone marrow and plasma cells that produce antibodies.
(source:internet, reference only)